Stock Events

Sernova 

€0.2
66
+€0.01+4.62% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
85.44M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

12JunExpected
Q4 2021
Q1 2022
Q2 2022
Q2 2023
Q4 2023
Q4 2023
Q1 2024
-0.03
-0.02
-0.02
-0.01
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PSH.XETRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vericel
VCEL
Mkt Cap2.27B
Vericel Corporation specializes in cell therapies for markets similar to Sernova's, making them direct competitors in the regenerative medicine space.
Biolife Solutions
BLFS
Mkt Cap921.38M
BioLife Solutions provides bioproduction tools and services, including cell and gene therapy solutions, competing in the same support and supply chain as Sernova.
Mesoblast
MESO
Mkt Cap883.74M
Mesoblast Limited focuses on regenerative medicine, specifically in areas of inflammation and cardiovascular disease, overlapping with Sernova's therapeutic targets.
Brainstorm Cell Therapeutics
BCLI
Mkt Cap25.66M
Brainstorm Cell Therapeutics develops adult stem cell therapies for neurodegenerative diseases, competing with Sernova's approach to chronic disease treatment through innovative therapies.
CRISPR Therapeutics
CRSP
Mkt Cap4.51B
CRISPR Therapeutics is focused on gene editing, a cutting-edge area of medicine that competes indirectly with Sernova's cell therapy and regenerative medicine technologies.
Editas Medicine
EDIT
Mkt Cap377.47M
Editas Medicine operates in the gene editing space, which represents a competitive alternative to Sernova's cell-based therapies for treating various diseases.
Intellia Therapeutics
NTLA
Mkt Cap2.2B
Intellia Therapeutics is another key player in the gene editing field, offering therapeutic solutions that could potentially rival Sernova's cell therapy approach.
Sangamo Therapeutics
SGMO
Mkt Cap66.92M
Sangamo Therapeutics focuses on genomic medicine, including gene therapy, gene editing, and cell therapy, directly competing with Sernova's technology in multiple areas.
Bluebird bio
BLUE
Mkt Cap100.95M
bluebird bio specializes in gene therapies for severe genetic diseases and cancer, competing with Sernova's therapeutic approaches in terms of innovative treatments for chronic conditions.

About

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.
Show more...
CEO
Ms. Cynthia Pussinen
Country
CA
ISIN
CA81732W1041
WKN
000A0LBCR

Listings